NPM1 and acute myeloid leukemia: Furthermore, NPM1 and CEBPA mutated AML, while generally sensitive to induction chemotherapy, demonstrate inconsistent long-term outcomes due to high relapse rates (Shi et al., 2024; Su et al., 2022; Suzuki et al., 2005; Wang et al., 2020).